Cytopia zeroes in on brain

By Kate McDonald
Monday, 17 November, 2008

Melbourne biotech Cytopia has commencing dosing patients in its Phase Ib/II trial of its vascular disrupting agent CYT997 in glioblastoma multiforme.

The trial will investigate the activity of CYT997 in combination with carboplatin and etoposide, common anti-cancer drugs.

CYT997 has been shown to ablate tumour blood vessels as well as inhibiting tubulin, thus affecting tumour cell replication. The compound is also being tested in multiple myeloma.

The trial will be held at Frankston Hospital in Victoria, with a second site in Sydney planned.

Related News

SEQ koala population carries immunity to retrovirus

Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...

RSV immunisation program for babies slashes hospital stays

An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...

A targeted treatment option for psoriasis

New research from MedUni Vienna paves the way for the development of a therapy that not only...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd